Inclusion Criteria:

          1. Patients with unequivocal documented (including histological confirmation of
             Glioblastoma-GB- at the primary diagnosis) evidence of first progression/recurrence of
             GB on MRI, as defined by RANO criteria

          2. Patients with :

               -  for Cohorts 1, 2a, and 3: at least 1 measurable lesion

               -  for Cohort 2b: no measurable enhancing disease

          3. Patients with an age ≥ 18 years old

          4. Patients who are human leukocyte antigen (HLA)-A2 positive

          5. Patients with an Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2 or
             Karnofsky performance status ≥ 70

          6. Patients should have received standard primary therapy, including surgery (biopsy,
             incomplete or complete resection), radiation, temozolomide, if applicable

               1. Radiation therapy must have been finished 28 days before first study treatment
                  administration

               2. Patients who received temozolomide as adjuvant therapy must have stopped the
                  treatment and have a wash-out period of 28 days before first study treatment
                  administration (6 weeks for nitrosoureas and 5 half lives for experimental
                  therapies)

               3. Patients with unmethylated methylguanine-DNA-methyltransferase (MGMT) promoter
                  can be included even if they have not received temozolomide prior to the
                  inclusion in this clinical study)

          7. Female patients of childbearing potential must have a negative serum pregnancy test
             within 72 hours prior to dosing

          8. Considering the embryofetal toxicity of the nivolumab shown on animals' models, the
             following recommendations for contraception must be followed:

             a. If not surgically sterile, female patients of childbearing potential age must use
             highly effective contraception from signing the Informed Consent Form (ICF) through 6
             months after the last treatment dose administered. Highly effective contraception
             included: i. Combined (estrogen and progesterone containing) hormonal contraception
             associated with inhibition of ovulation: Oral Intravaginal Transdermal ii.
             Progestogen-only hormonal contraception associated with inhibition of ovulation: Oral
             Injectable Implantable iii. Intrauterine device iv. Intrauterine hormone-releasing
             system v. Bilateral tubal occlusion vi. Sexual abstinence. In each case of delayed
             menstrual period (over 1 month between menstruations), confirmation of absence of
             pregnancy is strongly recommended. This recommendation also applies to women of
             childbearing potential with infrequent or irregular menstrual cycles.

             b. If not surgically sterile, male with female partner of childbearing potential must
             use condom from signing the ICF through 8 months after the last treatment dose
             administered. Males must ensure that their partners of childbearing potential use
             highly effective contraception also.

          9. Patients having received the information sheet and who have provided written informed
             consent prior to any study-related procedures

         10. Patients willing and able to comply with the scheduled visits, treatment plan,
             laboratory tests, and other study procedures indicated in the protocol.

        Exclusion Criteria:

          1. Patients treated with dexamethasone > 2 mg/day or equivalent (i.e., 13 mg/day of
             prednisone) within 14 days before the first EO2401 administration, unless required to
             treat an adverse event (AE) Note: The criterion implios the patient should not receive
             treatment with dexamethasone > 2 mg/day or equivalent at the actual time of a
             screening visit (single time point assessment), and within 14 days before the first
             EO2401 administration (unless required to treat AE); the latter part of the criterion
             should be checked at the time of treatment start.

          2. 2. Patients treated with radiotherapy, and cytoreductive therapy within 28 days (6
             weeks for nitrosoureas) before the first EO2401 administration. In addition, patients
             should not have received any prior treatment with compounds targeting PD-1, PD-L1,
             CTLA-4, or similar compounds where general resistance against therapeutic vaccination
             approaches might have developed; also, patients should not have received systemic
             anti-tumor treatment or radiotherapy for their progressive or first recurrent GB.

          3. Patients with tumors primarily located in the infra-tentorial segment

          4. Patients with known radiological evidence of extracranial metastases

          5. Patients with presence of new hemorrhage (excluding, stable Grade 1) or uncontrolled
             seizure

          6. Patients with significant leptomeningeal disease

          7. Patients with abnormal (≥ Grade 2 National Cancer Institute-Common Terminology
             Criteria for AEs [NCI-CTCAE] version 5.0) laboratory values for hematology, liver, and
             renal function (serum creatinine). In detail, the following values apply as exclusion
             criteria:

               1. Hemoglobin < 10 g/dL (6.2 mmol/L)

               2. White blood cell count decrease (< 3.0 × 109/L) or increase (> 10.0 × 109/L)

               3. Absolute neutrophil count decrease (< 1.5 × 109/L)

               4. Platelet count decrease (< 75 × 109/L)

               5. Bilirubin > 1.5 × upper limit of normal (ULN; according to the performing
                  laboratory's reference ranges)); Note, benign hereditary hyperbilirubinemia, e.g.
                  Gilbert's syndrome is permitted.

               6. Alanine aminotransferase > 3 × ULN

               7. Aspartate aminotransferase > 3 × ULN

               8. Gamma-glutamyltransferase > 2.5 × ULN

               9. Serum creatinine increase (> 1.5 × ULN)

              10. Abnormal thyroid function: 0.3 > thyroid-stimulating hormone > 5 μU(μunit)/mL and
                  8.6 > free T4 > 25 pmol/L.

          8. For patients who are planned to receive bevacizumab:

               1. Patients with nephrotic syndrome

               2. Patients with proteinuria ≥ 2g/24 hours

               3. Patients with history or active gastrointestinal perforation and fistula

               4. Significant surgical procedure in the 4 weeks preceding the start of treatment or
                  planned surgery

               5. Unhealed wound

               6. Patient with recent (4 weeks) history of hemoptysis of ½ teaspoon or more of red
                  blood

               7. Thrombotic episode within 6 months

               8. Uncontrolled diabetes mellitus or hypertension

               9. Posterior reversible encephalopathy syndrome

          9. Patients with persistent Grade 3 or 4 toxicities (according to NCI-CTCAE v5.0).
             Toxicities must be resolved since at least 2 weeks to Grade 1 or less. However,
             alopecia or other persisting toxicities Grade ≤ 2 not constituting a safety risk based
             on Investigator's judgment is acceptable

         10. Patients with contraindication to contrast-enhanced MRI

         11. Other malignancy or prior malignancy with a disease-free interval of less than 3 years
             except those treated with surgical intervention and an expected low likelihood of
             recurrence such as basal cell or squamous cell skin cancer, or carcinoma in situ.
             Patients with adequately treated basal cell or squamous cell skin cancer, or carcinoma
             in situ are eligible

         12. 12. Patients with clinically significant active infection, cardiac disease,
             significant medical or psychiatric disease/condition that, in the opinion of the
             Investigator, would interfere with the evaluation of EO2401 or interpretation of
             patient safety or study results or that would prohibit the understanding or rendering
             of informed consent (i.e. only consent able patients can be enrolled in the study) and
             compliance with the requirements of the protocol - including (but not limited to):

               1. Bacterial sepsis or other similarly severe infections

               2. New York Heart Association > Grade 2 congestive heart failure within 6 months
                  prior to study entry

               3. Uncontrolled or significant cardiovascular disease, including:

             i. Myocardial infarction within 6 months prior to obtaining informed consent ii.
             Uncontrolled/unstable angina within 6 months prior to obtaining informed consent iii.
             Diagnosed or suspected congenital long QT syndrome iv. Any history of clinically
             significant ventricular arrhythmias (such as ventricular tachycardia, ventricular
             fibrillation, or Torsades de pointes) d. Stroke within 6 months prior obtaining
             informed consent e. Concurrent neurodegenerative disease f. Dementia or significantly
             altered mental status.

         13. Patients with suspected autoimmune or active autoimmune disorder or known history of
             an autoimmune neurologic condition (e.g., Guillain-Barré syndrome) Note, patients with
             vitiligo, type I diabetes mellitus, hypothyroidism due to autoimmune condition only
             requiring hormone replacement therapy, psoriasis not requiring systemic therapy, or
             conditions not expected to recur in the absence of an external trigger are permitted
             to enroll

         14. Patients with history of solid organ transplantation or hematopoietic stem cell
             transplantation

         15. Patients with history or known presence of tuberculosis

         16. Pregnant and breastfeeding patients

         17. Patients with history or presence of human immunodeficiency virus and/or potentially
             active hepatitis B virus/hepatitis C virus

         18. Patients who have received live or attenuated vaccine therapy used for prevention of
             infectious diseases including seasonal (influenza) vaccinations within 4 weeks of the
             first dose of study drug

         19. Patients with a history of hypersensitivity to any excipient present in the
             pharmaceutical form of investigational medicinal product

         20. Patients under treatment with immunostimulatory or immunosuppressive medications,
             including herbal remedies, or herbal remedies known to potentially interfere with
             major organ function

         21. Patients with known drug and alcohol abuse

         22. Patients with known or underlying medical or psychiatric condition that, in the
             Investigator's opinion, would make the administration of study drug hazardous to the
             patient or obscure the interpretation of toxicity determination or AEs

         23. Patients who have received treatment with any other investigational agent, or
             participation in another clinical trial (clinical trial including active interventions
             are prohibited; participation in clinical trials for data collection purposes only are
             permitted) within 28 days prior to first study treatment administration and during the
             treatment period. Note, for investigational agents there should be a wash-out period
             of at least 28 days, or 5 half-lives if longer, before first study treatment
             administration

         24. Patients deprived of their liberty or under protective custody or guardianship.